Product-specific advice (Benserazide+levo­dopa) [Design Issues]

posted by Mikalai  – Belarus, 2018-01-09 15:37 (2680 d 21:24 ago) – Posting: # 18153
Views: 4,231

Dear all,
We plan to conduct the bioequivalence study of levodopa and benserazide. We approached several experts to write a protocol of the study. However, they informed us that there is a substantial lack of information on the pharmacokinetics of benserazide to finalize the protocol. We probably cannot ask our competent authority for advice because they may not have necessary information. Thus, we have several important questions in relation to benserazide.

Should we quantify in serum only Benserazide or its metabolite, or both?

What are criteria for bioequivalence (bioequivalence should be established only on the levodopa data or on the data of both components? bioequivalence acceptance criteria?)?

What is the best design for the study?

Any suggestions where and from whom we can obtain reliable advice on the above-mentioned issues will be appreciated.
Sincerely,
Mikalai


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
106 visitors (0 registered, 106 guests [including 63 identified bots]).
Forum time: 14:02 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5